Showing 41-50 of 2038 results for "".
Eye Makeup Trends and Eye Health
https://modernod.com/topics/ocular-surface/eye-makeup-trends-and-eye-health/38805/Staying aware of the latest beauty fads can help you educate your patients and safeguard their ocular health and vision.How to Stay Current
https://modernod.com/topics/imagingdiagnostics/how-to-stay-current/39062/Having the latest diagnostic equipment gives you an edge when it comes to attracting patients and referrals.Ready to Embrace the Newest Dry Eye Drop?
https://modernod.com/articles/significant-findings/ready-to-embrace-the-newest-dry-eye-drop/37850/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatFirst Robotic Cataract Surgery Performed
https://modernod.com/podcasts/eyewire-news-the-podcast/first-robotic-cataract-surgery-performed/39875/Uday Devgan, MD, shares his experience performing the world’s first robotic cataract surgery; Konan Medical receives CE Mark for its objectiveFIELD Analyzer perimetry device; and Biotech Healthcare launches a new full visual range EDOF IOL. Learn more about your ad choices. Visit megaphone.fm/adchoTryptyr Now Available in US
https://modernod.com/podcasts/eyewire-news-the-podcast/tryptyr-now-available-in-us/37095/Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoicesHarrow Adds Biosimilars to US Portfolio
https://modernod.com/podcasts/eyewire-news-the-podcast/harrow-adds-biosimilars-to-us-portfolio/37094/Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoicesFirst Myopia Drug Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/first-myopia-drug-approved-in-europe/37088/The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoicesLenz Therapeutics' Vizz Commerically Launched
https://modernod.com/podcasts/eyewire-news-the-podcast/lenz-therapeutics-vizz-commerically-launched/39874/A first-of-its-kind presbyopia eye drop is now commercially available; Lumibird introduces ICL Guru Integration on its ultrasound platform; and the makers of gene therapy candidates for retinal diseases provide clinical updates. Learn more about your ad choices. Visit megaphone.fm/adchoicesCE Certification for New Glaucoma Surgical Implant
https://modernod.com/podcasts/eyewire-news-the-podcast/ce-certification-for-new-glaucoma-surgical-implant/39868/Ciliatech obtains CE certification for the Intercil Uveal Spacer surgical implant; Zeiss receives CE mark for a new device that uses AI to automate OCT assessment; and the FDA extends the target action dates for two Eylea HD submissions. Learn more about your ad choices. Visit megaphone.fm/adchoicAlcon Acquires LumiThera
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-acquires-lumithera/37092/Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management. Learn more about your ad choices. Visit megaphone.fm/adchoices